{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:50:15Z","timestamp":1778784615890,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13318-024-00915-2","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T05:26:57Z","timestamp":1727155617000},"page":"763-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic Model of Drug Interaction of Tacrolimus with Combined Administration of CYP3A4 Inhibitors Voriconazole and Clarithromycin After Bone Marrow Transplantation"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2068","authenticated-orcid":false,"given":"Toshinori","family":"Hirai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Ino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ikejiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6445-4410","authenticated-orcid":false,"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"6","key":"915_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584\u201391.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"915_CR2","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92(7):2303\u201314.","journal-title":"Blood"},{"issue":"6","key":"915_CR3","first-page":"2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062\u20138.","journal-title":"Blood"},{"issue":"1","key":"915_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/bmt.2015.222","volume":"51","author":"Y Kanda","year":"2016","unstructured":"Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A, et al. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant. 2016;51(1):103\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"915_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"915_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bbmt.2015.08.027","volume":"22","author":"SK Khaled","year":"2016","unstructured":"Khaled SK, Palmer JM, Herzog J, Stiller T, Tsai NC, Senitzer D, et al. Influence of absorption, distribution, metabolism, and excretion genomic variants on tacrolimus\/sirolimus blood levels and graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):268\u201376.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"915_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12185-012-1057-2","volume":"95","author":"T Mori","year":"2012","unstructured":"Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(5):564\u20139.","journal-title":"Int J Hematol"},{"issue":"9","key":"915_CR8","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/ajt.14232","volume":"17","author":"T Vanhove","year":"2017","unstructured":"Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients. Am J Transplant. 2017;17(9):2372\u201380.","journal-title":"Am J Transplant"},{"issue":"6","key":"915_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13318-022-00790-9","volume":"47","author":"T Hirai","year":"2022","unstructured":"Hirai T, Ino K, Ikejiri M, Tawara I, Iwamoto T. Dual inhibition of CYP3A4 by voriconazole and clarithromycin influences tacrolimus pharmacokinetics: case series study. Eur J Drug Metab Pharmacokinet. 2022;47(6):889\u201393.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"915_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/jcph.605","volume":"56","author":"CK Imamura","year":"2016","unstructured":"Imamura CK, Furihata K, Okamoto S, Tanigawara Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2016;56(4):408\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"915_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00007691-199508000-00008","volume":"17","author":"TM Annesley","year":"1995","unstructured":"Annesley TM, Hunter BC, Fidler DR, Giacherio DA. Stability of tacrolimus (FK 506) and cyclosporin G in whole blood. Ther Drug Monit. 1995;17(4):361\u20135.","journal-title":"Ther Drug Monit"},{"issue":"18","key":"915_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.clinbiochem.2007.07.024","volume":"40","author":"LJ Langman","year":"2007","unstructured":"Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem. 2007;40(18):1378\u201385.","journal-title":"Clin Biochem"},{"issue":"2","key":"915_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FTD.0b013e31819c6a37","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Goffinet JS, O\u2019Morchoe S, Rosiere T, Maine GT, Labalette M, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit. 2009;31(2):198\u2013204.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"915_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/00007691-200412000-00011","volume":"26","author":"BG Keevil","year":"2004","unstructured":"Keevil BG, Newman S, Lockhart S, Howard SJ, Moore CB, Denning DW. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2004;26(6):650\u20137.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"915_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/jcph.1118","volume":"58","author":"O Campagne","year":"2018","unstructured":"Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM. Tacrolimus population pharmacokinetics and multiple CYP3A5 genotypes in black and white renal transplant recipients. J Clin Pharmacol. 2018;58(9):1184\u201395.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"915_CR16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/bcp.13595","volume":"84","author":"XB Lin","year":"2018","unstructured":"Lin XB, Li ZW, Yan M, Zhang BK, Liang W, Wang F, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84(7):1587\u201397.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"915_CR17","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1128\/AAC.01193-08","volume":"53","author":"K Abduljalil","year":"2009","unstructured":"Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, S\u00f6rgel F, Rodamer M, et al. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob Agents Chemother. 2009;53(7):2892\u2013901.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"915_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/cts.12956","volume":"14","author":"J Zhu","year":"2021","unstructured":"Zhu J, Campagne O, Torrice CD, Flynn G, Miller JA, Patel T, et al. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. Clin Transl Sci. 2021;14(3):908\u201318.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"915_CR19","first-page":"721","volume":"87","author":"E Thervet","year":"2010","unstructured":"Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"915_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/cpt.2348","volume":"110","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi I. Drug-drug-gene interactions: a call for clinical consideration. Clin Pharmacol Ther. 2021;110(3):549\u201351.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"915_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities? J Clin Pharmacol. 2019;59(3):309\u201325.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"915_CR22","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharm. 2020;59(11):1357\u201392.","journal-title":"Clin Pharm"},{"issue":"2","key":"915_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1128\/AAC.01123-08","volume":"53","author":"S Jeong","year":"2009","unstructured":"Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"915_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00498254.2011.631224","volume":"42","author":"S Zhang","year":"2012","unstructured":"Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica. 2012;42(5):409\u201316.","journal-title":"Xenobiotica"},{"key":"915_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2021.100384","volume":"38","author":"Y Yamaguchi","year":"2021","unstructured":"Yamaguchi Y, Akiyoshi T, Kawamura G, Imaoka A, Miyazaki M, Guengerich FP, et al. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metab Pharm. 2021;38: 100384.","journal-title":"Drug Metab Pharm"},{"issue":"12","key":"915_CR26","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.3390\/pharmaceutics14122739","volume":"14","author":"YC Zhao","year":"2022","unstructured":"Zhao YC, Xiao CL, Hou JJ, Li JK, Zhang BK, Xie XB, et al. The effect of voriconazole on tacrolimus in kidney transplantation recipients: a real-world study. Pharmaceutics. 2022;14(12):2739.","journal-title":"Pharmaceutics"},{"issue":"10","key":"915_CR27","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1111\/bcp.15385","volume":"88","author":"X Huang","year":"2022","unstructured":"Huang X, Zhou Y, Zhang J, Xiang H, Mei H, Liu L, et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. Br J Clin Pharmacol. 2022;88(10):4515\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"915_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00228-005-0091-x","volume":"62","author":"TM Polasek","year":"2006","unstructured":"Polasek TM, Miners JO. Quantitative prediction of macrolide drug\u2013drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol. 2006;62(3):203\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"915_CR29","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1345\/aph.1C117","volume":"36","author":"RB Ibrahim","year":"2002","unstructured":"Ibrahim RB, Abella EM, Chandrasekar PH. Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. Ann Pharmacother. 2002;36(12):1971\u20132.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"915_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00007691-200502000-00020","volume":"27","author":"PK Kunicki","year":"2005","unstructured":"Kunicki PK, Sobieszcza\u0144ska-Ma\u0142ek M. Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. Ther Drug Monit. 2005;27(1):107\u20138.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"915_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00194974","volume":"47","author":"K Wolter","year":"1994","unstructured":"Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK 506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol. 1994;47(2):207\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"915_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","volume":"64","author":"JC Gorski","year":"1998","unstructured":"Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O\u2019Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64(2):133\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"915_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00228-012-1339-x","volume":"69","author":"SK Quinney","year":"2013","unstructured":"Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, et al. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol. 2013;69(3):439\u201348.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"915_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.clpt.6100431","volume":"84","author":"MO Magnusson","year":"2008","unstructured":"Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstr\u00f6m R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"915_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/fcp.12882","volume":"37","author":"J Wen","year":"2023","unstructured":"Wen J, ChenYang ZM, Hu W, Xiao YW. Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats. Fundam Clin Pharmacol. 2023;37(4):843\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"915_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.bbmt.2018.12.766","volume":"25","author":"IS Hamadeh","year":"2019","unstructured":"Hamadeh IS, Zhang Q, Steuerwald N, Hamilton A, Druhan LJ, McSwain M, et al. Effect of CYP3A4, CYP3A5, and ABCB1 polymorphisms on intravenous tacrolimus exposure and adverse events in adult allogeneic stem cell transplant patients. Biol Blood Marrow Transplant. 2019;25(4):656\u201363.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"915_CR37","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3390\/ijms20102413","volume":"20","author":"K Suetsugu","year":"2019","unstructured":"Suetsugu K, Mori Y, Yamamoto N, Shigematsu T, Miyamoto T, Egashira N, et al. Impact of CYP3A5, POR, and CYP2C19 polymorphisms on trough concentration to dose ratio of tacrolimus in allogeneic hematopoietic stem cell transplantation. Int J Mol Sci. 2019;20(10):2413.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"915_CR38","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","volume":"25","author":"L Jeu","year":"2003","unstructured":"Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther. 2003;25(5):1321\u201381.","journal-title":"Clin Ther"},{"issue":"7","key":"915_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jcph.1093","volume":"58","author":"DE Coutant","year":"2018","unstructured":"Coutant DE, Hall SD. Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol. 2018;58(7):849\u201363.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"915_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/clpt.2014.143","volume":"96","author":"RD Harvey","year":"2014","unstructured":"Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96(4):449\u201357.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"915_CR41","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/pharmaceutics13111960","volume":"13","author":"A Chavant","year":"2021","unstructured":"Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of tacrolimus trough concentration in liver transplant patients: which role of inflammation? Pharmaceutics. 2021;13(11):1960.","journal-title":"Pharmaceutics"},{"issue":"6","key":"915_CR42","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/bcp.15662","volume":"89","author":"T Hirai","year":"2023","unstructured":"Hirai T, Morikawa Y, Onishi R, Nakatani Y, Nishikawa K, Inoue T, et al. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation. Br J Clin Pharmacol. 2023;89(6):1852\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"915_CR43","first-page":"565","volume":"44","author":"A Mimura","year":"2019","unstructured":"Mimura A, Yamaori S, Ikemura N, Katsuyama Y, Matsuzawa N, Ohmori S. Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation. J Clin Pharm Ther. 2019;44(4):565\u201371.","journal-title":"J Clin Pharm Ther"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00915-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00915-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00915-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:06:33Z","timestamp":1731074793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00915-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00915-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"13 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"No funding was received to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The Institutional Review Board of the Mie University Hospital approved the study design (approval number: H2022-180, September 30, 2022) based on the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from each patient to participate in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Toshinori Hirai and Takuya Iwamoto contributed to the study conception and design. Material preparation, data collection and analysis were performed by Toshinori Hirai, Takahiko Aoyama, Yasuhiro Tsuji, Kazuko Ino, and Makoto Ikejiri. The first draft of the manuscript was written by Toshinori Hirai, Takahiko Aoyama, Isao Tawara, and Takuya Iwamoto and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}